Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab SC vs IV in First-Line Advanced Gastric or GEJ Adenocarcinoma
NCT07043400Phase 3Recruiting
- Sponsor
- BeOne Medicines
- Start
- Aug 2025
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of tislelizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by BeOne Medicines. Started Aug 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07043400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07043400.